Form 8-K - Current report:
SEC Accession No. 0001641172-25-005428
Filing Date
2025-04-18
Accepted
2025-04-18 16:30:21
Documents
16
Period of Report
2025-04-17
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48372
2 ex16-1.htm EX-16.1 953
3 ex16-1_001.jpg GRAPHIC 126596
  Complete submission text file 0001641172-25-005428.txt   457550

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20250417.xsd EX-101.SCH 3976
5 XBRL DEFINITION FILE bfri-20250417_def.xml EX-101.DEF 30397
6 XBRL LABEL FILE bfri-20250417_lab.xml EX-101.LAB 37210
7 XBRL PRESENTATION FILE bfri-20250417_pre.xml EX-101.PRE 27416
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6855
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 25850665
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)